文献速递心脑血管急症重症综合管理与镇静镇痛

抗凝逆转对急性颅内出血死亡率的影响:系统评价与荟萃分析

Effect on Mortality of Anticoagulant Reversal in Acute Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurocrit Care · 2026-07-20
一句话结论口服抗凝相关颅内出血中,逆转治疗与死亡率降低相关(RR 0.78),但仅基于观察性研究,直接口服抗凝药亚组未达显著。

该系统评价与荟萃分析检索PubMed、Embase、Scopus和Web of Science(建库至2025年3月),纳入比较口服抗凝相关颅内出血患者接受逆转治疗与未逆转治疗死亡率的观察性研究,仅纳入对显著混杂变量进行适当统计控制的研究。共筛选8217项研究,最终纳入8项观察性研究、8777例有逆转治疗记录的患者。总体分析显示逆转与死亡率降低相关(RR 0.78,95%CI 0.67-0.91,p=0.002);非创伤性颅内出血亚组(8639例)同样显著(RR 0.77,95%CI 0.64-0.94,p=0.009),但仅用直接口服抗凝药的颅内出血亚组(3059例)未达显著(RR 0.91,95%CI 0.80-1.03,p=0.15)。结论认为现有证据有限,主要来自观察性研究,多数出血亚型研究不足,亟需随机临床试验。

要点

  • 口服抗凝相关颅内出血总体逆转治疗与死亡率降低相关(RR 0.78,95%CI 0.67-0.91,p=0.002),但证据仅来自观察性研究。
  • 非创伤性颅内出血、任何口服抗凝药亚组(8639例)逆转与死亡率降低相关(RR 0.77,95%CI 0.64-0.94,p=0.009)。
  • 仅直接口服抗凝药治疗的颅内出血亚组(3059例)逆转与死亡率降低无显著关联(RR 0.91,95%CI 0.80-1.03,p=0.15)。
  • 纳入研究均为观察性研究且需对显著混杂变量做统计控制,多数出血亚型研究不足,不能据此确立逆转治疗的普适推荐。
  • 原文指出亟需随机临床试验及更多良好控制的观察性研究以确定哪些患者真正从逆转治疗中获益。

适用人群与场景

  • 口服抗凝药相关颅内出血患者,纳入比较逆转治疗与未逆转治疗死亡率的研究人群;各出血亚型中多数研究不足。
  • 原文未提及急诊或ICU场景、病情阶段、具体纳入/排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体逆转药物、剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,检索PubMed、Embase、Scopus和Web of Science(建库至2025年3月),筛选8217项研究,最终纳入8项观察性研究、8777例有逆转治疗记录的患者。
  • 总体分析(所有颅内出血类型和所有抗凝药):逆转治疗与死亡率降低相关,RR 0.78(95%CI 0.67-0.91),p=0.002。
  • 非创伤性颅内出血、任何口服抗凝药亚组(8639例):逆转与死亡率降低相关,RR 0.77(95%CI 0.64-0.94),p=0.009。
  • 仅直接口服抗凝药治疗的颅内出血亚组(3059例):逆转与死亡率降低无显著关联,RR 0.91(95%CI 0.80-1.03),p=0.15。
  • 结局为死亡率,随访主要限于3个月。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入的8项研究均为观察性研究,仅纳入对显著混杂变量进行适当统计控制的研究。
  • 局限:证据主要来自观察性研究;多数出血亚型研究不足;直接口服抗凝药亚组未显示显著获益;原文强调亟需随机临床试验。

对床旁实践的改变

  • 原文提示:在口服抗凝相关颅内出血中,逆转治疗与死亡率降低的关联主要来自观察性研究,且直接口服抗凝药亚组未达显著,床旁决策时不能将总体汇总结果等同于对所有抗凝药、所有出血亚型的确证获益。
  • 原文未提及具体适用与不适用人群、常见陷阱或可改变的具体做法。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Reversal treatment is used to counterbalance effects of oral anticoagulation in intracranial hemorrhages. Despite effects on reducing hematoma expansion, the impact on mortality remains uncertain. Our aim was to assess the effects of reversal treatment on mortality in various forms of oral anticoagulant-associated intracranial hemorrhage.

METHODS: Systematic searches were performed in the electronic databases of PubMed, Embase, Scopus, and Web of Science from database inception to March 2025. We included studies that compared mortality between patients receiving reversal treatment vs. non-reversal in oral-anticoagulant-associated intracranial hemorrhages. Only studies with appropriate statistical controlling for significant confounding variables were included. Data extraction and synthesis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Data were summarized and pooled effect estimates were presented. Outcome was mortality, and primarily with a follow-up limited to 3 months.

RESULTS: A total of 8217 studies were screened; 8 were ultimately included, all observational, and including 8777 participants with documented reversal treatment. For the overall analysis, when all types of intracranial hemorrhage and all types of anticoagulants were included, reversal was associated with reduced mortality (RR 0.78 (95% CI 0.67-0.91); p = 0.002). This association was also seen in the subgroup analysis of 8639 participants with nontraumatic intracerebral hemorrhage on any oral anticoagulant (RR 0.77 (95% CI 0.64-0.94); p = 0.009), but not among the 3059 participants with intracerebral hemorrhage treated with only direct oral anticoagulants (RR 0.91 (95% CI 0.80-1.03); p = 0.15).

CONCLUSIONS: Current evidence for reduced mortality following anticoagulant reversal in intracranial hemorrhage is limited and primarily derived from observational studies. Although pooled data suggest a potential treatment benefit across various types of intracranial hemorrhages and anticoagulants, most hemorrhage subtypes remain insufficiently studied. Going forward, there is a critical need for randomized clinical trials and additional well-controlled observational studies to determine which patients truly benefit from reversal treatment.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Tallroth M, Östlundh L, Büki A, et al. Effect on Mortality of Anticoagulant Reversal in Acute Intracranial Hemorrhage: A Systematic Review and Meta-analysis. Neurocrit Care. 2026. PMID: 42477258. doi:10.1007/s12028-026-02588-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。